Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/intubation -4% Improvement Relative Risk Hospitalization -3% c19early.org/e Botton et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 31,072,642 patients in France No significant difference in outcomes seen Botton et al., Research and Practice in Thrombos.., doi:10.1002/rth2.12743 Favors aspirin Favors control
No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease
Botton et al., Research and Practice in Thrombosis and Haemostasis, doi:10.1002/rth2.12743
Botton et al., No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without.., Research and Practice in Thrombosis and Haemostasis, doi:10.1002/rth2.12743
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 31 million people without cardiovascular disease in France, showing no significant difference in hospitalization or combined intubation/death with low dose aspirin prophylaxis.
risk of death/intubation, 4.0% higher, HR 1.04, p = 0.18, Cox proportional hazards.
risk of hospitalization, 3.0% higher, HR 1.03, p = 0.046, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Botton et al., 17 Jun 2022, retrospective, France, peer-reviewed, 7 authors.
Contact: jeremie.botton@ansm.sante.fr.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Received: 4 July 2021 | Revised: 6 April 2022 | Accepted: 20 April 2022 DOI: 10.1002/rth2.12743 BRIEF REPORT No association of low-­dose aspirin with severe COVID-­19 in France: A cohort of 31.1 million people without cardiovascular disease Jérémie Botton PhD, PharmD1 | Laura Semenzato MSc1 | 2 Julie Dupouy PhD, MD | Rosemary Dray-­Spira PhD, MD1 | Alain Weill MD1 Olivier Saint-­Lary PhD, MD3 | Mahmoud Zureik PhD, MD1,3 1 EPI-­PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-­Denis, France 2 MSPU de Pins Justaret, University Paul Sabatier Toulouse III, UMR 1295 Inserm Univ. Paul Sabatier, F-­31000, Toulouse, France 3 University Paris-­Saclay, UVSQ, Univ. Paris-­Sud, Inserm, Primary Care and Prevention, CESP, Villejuif, France Correspondence Jérémie Botton, EPI-­PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, 143/147 Bd Anatole France 93285 Saint-­ Denis Cedex, France. Email: jeremie.botton@ansm.sante.fr Funding information None. | Abstract Background: Aspirin at low doses has been reported to be a potential drug candidate to treat or prevent severe coronavirus disease 2019 (COVID-­19). Objectives: We aimed to explore whether low-­dose aspirin used for primary cardiovascular prevention was associated with a lower risk of severe COVID-­19. Method: A large cohort of patients without known cardiovascular comorbidities was constructed from the entire French population registered in national health care databases. In total, 31.1 million patients aged ≥40 years, including 1.5 million reimbursed for low-­dose aspirin at least at three time points during the 6 months before the epidemic, were followed until hospitalization with a COVID-­19 diagnosis or intubation/ death for hospitalized patients. Results: Cox models adjusted for age and sex showed a positive association between low-­dose aspirin and the risk of hospitalization (hazard ratio [HR], 1.33; 95% confidence interval (CI), 1.29-­1.37]) or death/intubation (HR, 1.40 [95% CI, 1.33-­1.47]). In fully adjusted models, associations were close to null (HR, 1.03 [95% CI, 1.00-­1.06] and 1.04 [95% CI, 0.98-­1.10], respectively). Conclusion: There was no evidence for an effect of low-­dose aspirin for primary cardiovascular prevention in reducing severe COVID-­19. Handling Editor: Dr Suzanne Cannegieter KEYWORDS aspirin, COVID-­19, pharmacoepidemiology, primary cardiovascular prevention, public health Jérémie Botton and Laura Semenzato contributed equally to this work. This is an open access article under the terms of the Creative Commons Attribution-­NonCommercial-­NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-­commercial and no modifications or adaptations are made. © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). Res Pract Thromb Haemost. 2022;6:e12743. https://doi.org/10.1002/rth2.12743  wileyonlinelibrary.com/journal/rth2 | 1 of 6 2 of 6 | BOTTON et al. Essentials • Aspirin at low doses has been reported to be a potential drug candidate to treat or prevent severe COVID-­19. • We built a large cohort of 31.1..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit